Behind the scenes at the PBAC Outgoing RACGP representative Rashmi Sharma pulls back the curtain after 10 years on the Pharmaceutical Benefits Advisory Committee.
Protecting your practice from a notifiable data breach The RACGP has again collaborated with the Office of the Australian Information Commissioner for Privacy Awareness Week.
Old doc, new data: Canaglifozin Can-I-get-a-flozin? Dr Casey Parker examines new evidence for the diabetes medication.
Metabolic disorder drug listed on the PBS The listing will save patients with hyperphenylalaninemia more than $90,000 a year.
Government’s NDIS growth figures ‘pretty meaningless’: GP Dr James Best discusses the gap between the Government’s positive depiction of the NDIS and the experiences of people navigating the scheme.
Potentially ‘life changing’ arthritis drug listed on PBS Tofacitinib will be listed despite lingering concerns related to an increased risk of blood clots and potentially death when taken in high doses.
Cheaper treatments for cancer, Parkinson’s and motor neurone patients Changes to the Pharmaceutical Benefits Scheme will see some patients saving up to $300,000 per year.
Important psoriatic arthritis drug listed on the PBS Ixekizumab is available for patients with the life-long condition, which causes joints to become stiff, painful and often swollen.
Four ‘breakthrough’ cancer drugs added to the PBS Almost 2000 people with leukaemia, advanced kidney cancer, bladder cancer and liver cancer will have affordable access to new treatment options.
PBS listing could save psoriasis patients tens of thousands a year Two effective – yet underutilised – psoriasis treatments have been added to the PBS, potentially reducing the cost by $32k per year.